Intellia Therapeutics in the NEWS February 26, 2026, Intellia Therapeutics, Inc. (NTLA), reported business updates and financial results for the fourth quarter and year ended December 31, 2025. From Intellia Therapeutics Intellia President and Chief Executive Officer John Leonard, M.D, said, “2025 was a time of accomplishment and resiliency for Intellia . . . This content is for paid subscribers. Please click here to subscribe or here to log …
Novo Nordisk in the NEWS February 24, 2026 – Novo Nordisk (NVO) announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Merck - Human Health Business RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK) - known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its . . . This content …
Johnson & Johnson in the NEWS Yesterday, February 18, 2026, Johnson & Johnson (JNJ) announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and . . . This content …
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., February 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA) - a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement . . . This content is for …
Bio-Techne Corp Q2 Financial Results Yesterday, February 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (TECH) reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights Second quarter revenue . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
